97 results on '"A. Klein-Goldberg"'
Search Results
2. 1080 Tumor Treating Fields (TTFields) application induces a pro-inflammatory phenotype in macrophages
3. P1.12-10 Sensitization of Cancer Cells to Tumor Treating Fields (TTFields) via Inhibition of the PI3K/AKT Signaling Pathway
4. 1080 Tumor Treating Fields (TTFields) application induces a pro-inflammatory phenotype in macrophages
5. Tumor Treating Fields (TTFields) Concomitant with Immune Checkpoint Inhibitors Are Therapeutically Effective in Non-Small Cell Lung Cancer (NSCLC) In Vivo Model
6. Abstract 4860: PI3K inhibition sensitize cancer cells to tumor treating fields (TTFields)
7. Abstract 1738: Sensitizing cancer cell to doxorubicin by tumor treating fields (TTFields)-induced, elevated membrane permeability
8. Genomic alterations drive metastases formation in pancreatic ductal adenocarcinoma cancer: deciphering the role of CDKN2A and CDKN2B in mediating liver tropism
9. Tumor Treating Fields (TTFields) Concomitant with Immune Checkpoint Inhibitors Are Therapeutically Effective in Non-Small Cell Lung Cancer (NSCLC) In Vivo Model
10. PI3K Inhibition Sensitized Cancerous Cells to Tumor Treating Fields (TTFields)
11. Enhancing Cancer Cell Membrane Permeability by Application of Tumor Treating Fields (TTFields)
12. 860 In vivoeffectiveness of tumor treating fields (TTFields) concomitant with immune checkpoint inhibitors in non-small cell lung cancer (NSCLC)
13. CSIG-41. SENSITIZING CANCER CELLS TO TUMOR TREATING FIELDS (TTFIELDS) BY INHIBITION OF PI3K
14. Tumor Treating Fields (TTFields) Delivery to Macrophages Promotes a Pro-Inflammatory Phenotype
15. 860 In vivoeffectiveness of tumor treating fields (TTFields) concomitant with immune checkpoint inhibitors in non-small cell lung cancer (NSCLC)
16. P10.11.B Re-sensitizing cancer cells to Tumor Treating Fields (TTFields) through PI3K/AKT/mTOR pathway inhibition
17. EP16.01-016 Tumor Treating Fields (TTFields) Application Promotes a Pro-inflammatory Phenotype in Macrophages
18. EP16.03-028 Cancer Cells May be Re-sensitized to Tumor Treating Fields (TTFields) Through Inhibition of the PI3K/AKT/mTOR Pathway
19. The role played by the microenvironment in site-specific metastasis
20. EP.03G.03 Tumor Treating Fields (TTFields) Induce Pro-Inflammatory Phenotype Skewing of Macrophages
21. A Transgenic Model Reveals the Role of Klotho in Pancreatic Cancer Development and Paves the Way for New Klotho-Based Therapy
22. Enhancing Cancer Cell Membrane Permeability by Application of Tumor Treating Fields (TTFields)
23. Genomic alterations drive brain metastases formation in colorectal cancer: The role of IRS2
24. Abstract 1801: Application of Tumor Treating Fields (TTFields) to cancer cells enhances their membrane permeability
25. Abstract 2659: Inhibition of PI3K sensitized cancer cells to Tumor Treating Fields (TTFields)
26. Abstract 1305: Tumor Treating Fields (TTFields) promote a pro-inflammatory phenotype in macrophages
27. Abstract 4860: PI3K inhibition sensitize cancer cells to tumor treating fields (TTFields)
28. Abstract 1738: Sensitizing cancer cell to doxorubicin by tumor treating fields (TTFields)-induced, elevated membrane permeability
29. EP16.01-016 Tumor Treating Fields (TTFields) Application Promotes a Pro-inflammatory Phenotype in Macrophages
30. Inhibition of PI3K restores cancer cell sensitivity to Tumor Treating Fields (TTFields)
31. Enhancing membrane permeability of cancer cells through delivery of Tumor Treating Fields (TTFields)
32. 726 Tumor Treating Fields (TTFields) induce an altered polarization program in M1/M2 macrophages
33. CSIG-41. SENSITIZING CANCER CELLS TO TUMOR TREATING FIELDS (TTFIELDS) BY INHIBITION OF PI3K
34. Enhancing membrane permeability of cancer cells through delivery of Tumor Treating Fields (TTFields)
35. Inhibition of PI3K restores cancer cell sensitivity to Tumor Treating Fields (TTFields)
36. A Transgenic Model Reveals the Role of Klotho in Pancreatic Cancer Development and Paves the Way for New Klotho-Based Therapy
37. DDRE-46. REDUCED CANCER CELL SENSITIVITY TO TUMOR TREATING FIELDS (TTFields) THROUGH ACTIVATION OF THE PI3K/AKT/mTOR SIGNALING PATHWAY CAN BE MITIGATED USING PI3K INHIBITORS OR PI3K/mTOR DUAL INHIBITORS
38. EXTH-74. INCREASING CANCER CELL MEMBRANE PERMEABILITY THROUGH APPLICATION OF TUMOR TREATING FIELDS (TTFIELDS)
39. 726 Tumor Treating Fields (TTFields) induce an altered polarization program in M1/M2 macrophages
40. Activated Phosphoinositide 3-Kinase/AKT/mTOR Signaling Confers Resistance to Tumor Treating Fields (TTFields)
41. P10.11.B Re-sensitizing cancer cells to Tumor Treating Fields (TTFields) through PI3K/AKT/mTOR pathway inhibition
42. Tumor Treating Fields (TTFields) application to cancerous cell lines elevates membrane permeability
43. Abstract 1305: Tumor Treating Fields (TTFields) promote a pro-inflammatory phenotype in macrophages
44. Abstract 1801: Application of Tumor Treating Fields (TTFields) to cancer cells enhances their membrane permeability
45. Cancer cell permeability is increased after Tumor Treating Fields (TTFields) application
46. Abstract 1692: A novel immunoregulatory role of tumor treating fields (TTFields) on macrophage polarization
47. Abstract 1382: Targeting Akt signaling pathway potentiates the antitumor effect of Tumor Treating Fields (TTFields) in vitro
48. EXTH-69. INCREASED CANCER CELL PERMEABILITY FOLLOWING TUMOR TREATING FIELDS (TTFIELDS) APPLICATION IN VITRO
49. DDRE-46. REDUCED CANCER CELL SENSITIVITY TO TUMOR TREATING FIELDS (TTFields) THROUGH ACTIVATION OF THE PI3K/AKT/mTOR SIGNALING PATHWAY CAN BE MITIGATED USING PI3K INHIBITORS OR PI3K/mTOR DUAL INHIBITORS
50. Activated Phosphoinositide 3-Kinase/AKT/mTOR Signaling Confers Resistance to Tumor Treating Fields (TTFields)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.